Surat Samachar

Lyme Disease Pipeline: Emerging products, and therapies leading the Lyme disease market ahead

 Breaking News
  • No posts were found

Lyme Disease Pipeline: Emerging products, and therapies leading the Lyme disease market ahead

March 27
15:30 2020
Lyme Disease Pipeline: Emerging products, and therapies leading the Lyme disease market ahead

Lyme Disease Pipeline
DelveInsight’s Lyme Disease Pipeline Report delivers an in-depth understanding of the disease, marketed therapies, pipeline products, their MoA, RoA, and their Lyme disease market share in the 7MM for the study period 2017-30.

DelveInsight’s ‘Lyme disease Pipeline Insight, 2020’ report covers pipeline landscape including Lyme disease treatment landscape including therapies, regulatory guidelines, commercial assessment and clinical evaluation. The report offers all the products from the pre-clinical developmental phase to the marketed phase, with an all-inclusive description of the drug, mechanism of action, clinical studies, NDA approvals (if any), and product development activities

for 7MM

  • The US
  • EU5
  • Japan

For the Study period 2017-30.

The Lyme disease Market report also sheds light on the novel technologies, unmet needs, Lyme disease partnerships, licensing, mergers and acquisition, funding, titles/labels, and other product-related details along with Lyme disease market drivers and barriers.

 

Know More about the Report.

 

Lyme disease market: Disease understanding

Lyme disease is an infectious disease caused by the Bacterium Borrelia burgdorferi, thus also known as Lyme burgdorferi. It is transmitted by the bite of black-legged ticks. The Lyme disease symptoms include headache, fever, fatigue, chills, and in most severe cases, people may begin to experience facial palsy, arthritis, and heart palpitations.

Lyme disease incidence has doubled since 1991, from about 4 cases per 100,000 people to 8 per 100,000 people, says CDC.

As per DelveInsight, total Lyme disease incident population in the 7MM was recorded 492,398 cases, whereas total diagnosed Lyme disease incident population was 396,761 for the study period 2017-28.

Lyme Disease Pipeline

Almost 70-80% of people who are affected by the Lyme disease develop rashes.

The most viable option for Lyme disease treatment is Antibiotics. However, from past years, efforts are being made to prevent Lyme from affecting people.

At Present Lyme disease treatment market constitutes mainly of:  

  • Antibiotics comprising Tetracycline (Doxycycline)
  • Penicillins (Amoxicillin and Benzathine Penicillin)
  • Cephalosporins (Cefuroxime, Ceftriaxone and Cefotaxime)
  • Macrolides (Azithromycin and clarithromycin)

 

Lyme disease market has a weak pipeline with only a single emerging pipeline product – VLA15 (Valneva).

Expected launch of potential therapies (currently only one i.e., VLA15) shall increase market size in the coming years. Moreover, an increase in diagnosed Lyme disease incident population shall also increase the Lyme disease market size.

 

Request for sample pages.

 

Report Highlights

  • Comprehensive understanding of disease pathogenesis
  • Novel therapies
  • Changing Lyme Disease marker trends
  • Companies and academics working in Lyme Disease market
  • Challenges present and opportunities untapped in the Lyme Disease market
  • R&D influencing Lyme Disease market
  • A detailed pharma players’ portfolio involved in fuelling the Lyme Disease treatment market
  • In-depth analysis of the Lyme Disease pipeline assets

 

Table of Contents

1. Report Introduction

2. Lyme Disease

3. Lyme Disease Current Treatment Patterns

4. Lyme Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Lyme Disease Late Stage Products (Phase-III)

7. Lyme Disease Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lyme Disease Discontinued Products

13. Lyme Disease Product Profiles

14. Lyme Disease Key Companies

15. Lyme Disease Key Products

16. Dormant and Discontinued Products

17. Lyme Disease Unmet Needs

18. Lyme Disease Future Perspectives

19. Lyme Disease Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; will be provided in the final report

 

Read More.

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/